263 related articles for article (PubMed ID: 18019828)
1. Liposomal daunorubicin as treatment for Kaposi's sarcoma.
Petre CE; Dittmer DP
Int J Nanomedicine; 2007; 2(3):277-88. PubMed ID: 18019828
[TBL] [Abstract][Full Text] [Related]
2. Use of liposomal anthracyclines in Kaposi's sarcoma.
Krown SE; Northfelt DW; Osoba D; Stewart JS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):36-52. PubMed ID: 15717737
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD003256. PubMed ID: 25221796
[TBL] [Abstract][Full Text] [Related]
5. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
[TBL] [Abstract][Full Text] [Related]
8. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
Chew T; Jacobs M
Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Hjortsberg C; Persson U; Lidbrink E; Bennett C
Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
[TBL] [Abstract][Full Text] [Related]
13. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil.
Vanni T; Fonseca BA; Polanczyk CA
HIV Clin Trials; 2006; 7(4):194-202. PubMed ID: 17065031
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel for treating KS.
Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
Money-Kyrle JF; Bates F; Ready J; Gazzard BG; Phillips RH; Boag FC
Clin Oncol (R Coll Radiol); 1993; 5(6):367-71. PubMed ID: 8305357
[TBL] [Abstract][Full Text] [Related]
19. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534
[TBL] [Abstract][Full Text] [Related]
20. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma.
Presant CA; Scolaro M; Kennedy P; Blayney DW; Flanagan B; Lisak J; Presant J
Lancet; 1993 May; 341(8855):1242-3. PubMed ID: 8098393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
